DEL VECCHIO, SILVANA
 Distribuzione geografica
Continente #
NA - Nord America 1.890
EU - Europa 957
AS - Asia 336
AF - Africa 48
Continente sconosciuto - Info sul continente non disponibili 2
SA - Sud America 1
Totale 3.234
Nazione #
US - Stati Uniti d'America 1.847
IT - Italia 316
CN - Cina 287
UA - Ucraina 153
FI - Finlandia 124
IE - Irlanda 109
DE - Germania 87
SE - Svezia 69
CI - Costa d'Avorio 48
NL - Olanda 46
CA - Canada 43
GB - Regno Unito 38
IN - India 13
VN - Vietnam 12
HK - Hong Kong 10
SG - Singapore 6
BE - Belgio 4
FR - Francia 4
KR - Corea 3
RU - Federazione Russa 3
TR - Turchia 3
EU - Europa 2
IS - Islanda 2
DK - Danimarca 1
ID - Indonesia 1
JP - Giappone 1
PE - Perù 1
RO - Romania 1
Totale 3.234
Città #
Chandler 322
Jacksonville 198
Princeton 125
Millbury 124
Boston 112
Woodbridge 107
Naples 88
Nanjing 85
Wilmington 68
Ashburn 51
Amsterdam 46
Ottawa 39
Houston 37
Ann Arbor 34
Nanchang 34
Beijing 33
Des Moines 30
Napoli 28
Hebei 27
Shenyang 25
Tianjin 22
Lawrence 21
Jiaxing 19
Norwalk 18
Changsha 13
Dong Ket 12
Falls Church 12
Milan 12
Kronberg 10
Dublin 9
Boardman 8
Hong Kong 7
Kunming 7
Seattle 7
Fairfield 6
Pune 6
Rome 6
Dearborn 5
Zhengzhou 5
Bacoli 4
Courcelles 4
Orange 4
San Francisco 4
San Nicola la Strada 4
Washington 4
Caserta 3
Casoria 3
Castellammare Di Stabia 3
Crispano 3
Giugliano in Campania 3
Lappeenranta 3
Singapore 3
Toronto 3
Albignasego 2
Bari 2
Bergamo 2
Brindisi 2
Capodrise 2
Cava 2
Cesano Maderno 2
Daejeon 2
Guangzhou 2
Hangzhou 2
Helsinki 2
Indiana 2
Lacco Ameno 2
Los Angeles 2
Mumbai 2
Nocera Inferiore 2
Osimo 2
Portici 2
Redwood City 2
Reggio Nell'emilia 2
Reykjavik 2
Sarno 2
Shanghai 2
Shenzhen 2
Stockholm 2
Tolentino 2
Venezia 2
Villarosa 2
Arezzo 1
Augusta 1
Avigliano 1
Bellona 1
Bloomfield 1
Castel Volturno 1
Changchun 1
Copenhagen 1
Denpasar 1
Edinburgh 1
Florence 1
Forio 1
Forlì 1
Gambatesa 1
Genova 1
Grumo Nevano 1
Hicksville 1
Istanbul 1
Jinan 1
Totale 1.941
Nome #
2-deoxy-2[F-18] fluoro-D-GLUCOSE POSITRON EMISSION TOMOGRAPHY Deauville scale and core-needle biopsy to determine successful management after six doxorubicin, bleomycin, vinblastine and dacarbazine cycles in advanced-stage Hodgkin lymphoma 63
99mTc-MIBI in the evaluation of breast cancer biology 54
Tumor induced osteomalacia: a systematic review and individual patient's data analysis 54
Bone marrow uptake of 99mTc-MIBI in patients with multiple myeloma 51
Tc99m-sestaMIBI uptake in nonsecretory multiple myeloma 44
Washout of 99mTc-Sestamibi in predicting response to chemotherapy in patients with multiple myeloma. 43
Bcl-2 overexpression prevents 99mTc-MIBI uptake in breast cancer cell lines. 43
Functional imaging of multidrug resistant phenotype by 99mTc-MIBI scan in patients with multiple myeloma 42
Epidermal growth factor (EGFR) and Transferrin (TRFR) receptor upregulation is induced by arabinoside cytosine (ARA-C) on human tumor cells. 41
2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography/computed tomography in primary extranodal lymphomas: treatment response evaluation and prognosis 41
Liposomal doxorubicin supercharge-containing front-line treatment in patients with advanced-stage diffuse large B-cell lymphoma or classical Hodgkin lymphoma: Preliminary results of a single-centre phase II study 39
Functional imaging of multidrug resistance in breast cancer. 39
Neutrophil extracellular traps as an adhesion substrate for different tumor cells expressing RGD-binding integrins. 38
Investigation of integrin expression in cancer stem cells isolated from glioblastoma patients 38
Coordinate up-regulation of Sp1 DNA-binding activity and urokinase receptor expression in breast carcima 36
Scintigraphic detection of multidrug resistance in cancer 36
111In-pentetreotide scintigraphy:procedure guidelines for tumor imaging 36
99mTc-MIBI in the evaluation of breast cancer biology 36
18F-FDG-PET/CT, 99mTc-MIBI and MRI in the prediction of outcome of patients with multiple myeloma: a comparative study 36
Dynamic coupling of 99mTc-MIBI efflux and apoptotic pathway activation in untreated breast cancer patients 35
Molecular imaging of tumor microenvironment: challenges and perspectives 35
PET/CT in cancer research: from preclinical to clinical applications. 34
Multimodal imaging with 18F-FDG-PET/CT and 111In-Octreotide SPECT in patients with metastatic medullary thyroid carcinoma 34
Heterogeneity of SSTR2 expression assessed by 68Ga-DOTATOC PET/CT using coefficient of variation in patients with neuroendocrine tumors 34
Detection of leptomeningeal involvement by 18F-FDG-PET/CT in a patient with non-Hodgkin lymphoma 33
Urokinase receptor interacts with avb5 vitronectin receptor, promoting urokinase-dependent cell migration in breast cancer 32
Tumor clearance of Technetium 99m-Sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer 32
99mTc-MIBI uptake is reduced in Bcl-2 overexpressing MCF-7 breast cancer cells 32
Breast tumor cell invasion and pro-invasive activity of cancer-associated fibroblasts co-targeted by novel urokinase-derived decapeptides 32
Scintimammography with 99mTc-MIBI versus dynamic MRI forn non-invasive characterization of breast masses 31
Vitronectin binding to urokinase receptor in human breast carcinoma 31
Bone scintigraphy and SPECT/CT in bisphosphonate-induced osteonecrosis of the jaw 31
Nuclear imaging in cancer theranostic 30
MIBI as prognostic factor in breast cancer 30
Nuclear Imaging of Apoptosis in Animal Tumor Models 29
Impact of COVID-19 pandemic on 2-[18F]FDG PET/CT imaging work-flow in a single medical institution: comparison among the three Italian waves 29
Technetium 99m sestamibi in multiple myeloma 28
Radiolabeling approaches for cholecystokinin B receptor imaging. 28
Predictive value of technetium-99m sestamibi in patients with multiple myeloma and potential role in the follow-up 28
In vivo detection of multidrug-resistant (MDR1) phenotype by 99mTc-Sestamibi scan in untreated breast cancer patients. 28
18F-FDG-PET/CT in the evaluation of bone marrow infiltration in patients with multiple myeloma. 28
Performance of FDG-PET/CT in solitary pulmonary nodule based on pre-test likelihood of malignancy: results from the ITALIAN retrospective multicenter trial 28
Fractional retention of 99mTc-sestamibi as an index of P-glycoprotein expression in untreated breast cancer patients. 27
Distribution of mediastinal lesions across multi-institutional, international, radiology databases 27
Annual Congress of the European Association of Nuclear Medicine Munich 2008 26
18F-FDG PET/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma 26
Sphingosine Kinase 1 (SphK1) overespression contributes to cetuximab resistance in human colrectal cancer. 26
Visual and volumetric parameters by 18F-FDG-PET/CT: a head to head comparison for the prediction of outcome in patients with multiple myeloma 26
Brain metastases unresponsive to immunotherapy detected by 18F-FDG-PET/CT in a patient with melanoma 26
Prediction of 2-[18F]FDG PET-CT SUVmax for Adrenal Mass Characterization: A CT Radiomics Feasibility Study 25
Molecular imaging: High-resolution detectors for early diagnosis and therapy monitoring of breast cancer. 25
Combined SPECT/CT and PET/CT for breast imaging 25
Early 18F-FDG uptake as a reliable imaging biomarker of T790M-mediated resistance but not MET amplification in non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors 25
Machine Learning and Texture Analysis of [18F]FDG PET/CT Images for the Prediction of Distant Metastases in Non-Small-Cell Lung Cancer Patients 25
Heterogeneity of glycolytic phenotype determined by 18F-FDG PET/CT using coefficient of variation in patients with advanced non-small cell lung cancer 24
Mammoscintigrafia e carcinoma mammario 24
Sestamibi and FDG-PET scans to support diagnosis of jaw osteonecrosis. 24
Anti-murine antibody response to mouse monoclonal antibodies: clinical findings and implications 24
Clinical studies with B72.3 in ovarian cancer and probe-guided tumor localization 24
Molecular breast imaging: First results from Italian-National-Institute-of-Health clinical trials. 24
99mTc-MIBI uptake in Bcl-2 overexpressing non-Hodgkin's lymphoma patients during drug-induced apoptosis. 24
Translational molecular imaging in exocrine pancreatic cancer. 24
ATM inhibition blocks glucose metabolism and amplifies the sensitivity of resistant lung cancer cell lines to oncogene driver inhibitors 23
Radiolabeling approches for cholecystokinin B receptor imaging 23
Usefulness of [111In-DTPA0] octreotide scintigraphy in a family with von Hippel-Lindau disease. 23
Metabolic tumor volume assessed by 18F-FDG-PET/CT for the prediction of outcome in patients with multiple myeloma 23
Automatic radiosynthesis of [F-18]-FBCHO-maleimide linker for affibody labelling 23
18F-FDG-PET/CT, 99mTc-MIBI and MRI in the evaluation of patients with multiple myeloma 23
99mTc-MIBI uptake in breast cancer cells during early phases of apoptosis induction with Staurosporine 23
Total metabolic tumor volume by 18F-FDG PET/CT for the prediction of outcome in patients with non-small cell lung cancer 23
Evaluation of the side effects of chemotherapy and radiotherapy on other organs 22
In Vitro and In Vivo Characterization of Indium-111 and Technetium-99m Labeled CCK-8 Derivatives for CCK-B Receptor Imaging 22
Human urokinase receptor concentration in malignant and benign breast tumors by in vitro quantitative autoradiography: comparison with urokinase levels. 22
La Medicina Nucleare in Oncologia 22
Reversal of Warburg effect and reactivation of oxidative phosphorylation by differential inhibition of EGFR signaling pathways in non-small cell lung cancer. 22
FDG-PET/CT imaging during the Covid-19 emergency: a southern Italian perspective 22
Use of 99mTc-sestamibi scintigraphy in multiple myeloma 21
Avid (67)Ga uptake in multiple myeloma relapsing after bone marrow transplant. 21
Molecular imaging: the emerging role of optical imaging in nuclear medicine. 21
Imaging of immunotherapy response in non-small cell lung cancer: challenges and perspectives. 21
Inhibition of early 99mTc-MIBI uptake by Bcl-2 anti-apoptotic protein overexpression in untreated breast carcinoma 20
3'-Deoxy-3'-18F-Fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non–small cell lung cancer 20
A new and selective radiolabeled alpha(V)beta(3) peptide antagonist as tracer in tumor diagnosis 20
A new and selective radiolabeled alpha(v)beta 3 peptide antagonist as tracer in tumor diagnosis 20
Permeabilità bronchiale transepiteliale. Basi funzionali ed implicazioni cliniche. 20
Combined imaging with 18F-FDG-PET/CT and 111In-labeled Octreotide SPECT for evaluation of thymic epithelial tumors 20
Risk-related 18F-FDG PET/CT and new diagnostic strategies in patients with solitary pulmonary nodule: the ITALIAN multicenter trial 20
Gefitinib induction of in vivo detectable signals by Bcl-2/Bcl-xL modulation of inositol trisphosphate receptor type 3. 19
A new role for nuclear medicine in multiple myeloma. 19
F-18-FDG-PET/CT, 99mTC-MIBI and MRI in the evaluation of patients with multiple myeloma 19
In vitro receptor imaging for characterization of human solid tumors. 18
Evaluation of metabolic response with 18F-FDG PET-CT in patients with advanced or recurrent thymic epithelial tumors. 18
Preclinical imaging in targeted cancer therapies. 17
Coordinate modulation of glycolytic enzymes and OXPHOS by imatinib in BCR-ABL driven chronic myelogenous leukemia cells. 17
Integrin-dependent cell adhesion to neutrophil extracellular traps through engagement of fibronectin in neutrophil-like cells 17
Endobronchial administration of iodine-131 B72.3 monoclonal antibody in patients with lung cancer. 16
European Association of Nuclear Medicine 16
Detection of colon cancer with radiolabelled monoclonal antibodies. 16
In vitro and in vivo evaluation of In-111-DTPAGlu-G-CCK8 for cholecystokinin-B receptor imaging 16
Monitoring reversal of MET-mediated resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer using 3'-deoxy-3'-[18F]-fluorothymidine positron emission tomography 16
Totale 2.787
Categoria #
all - tutte 15.753
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 15.753


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201925 0 0 0 0 0 0 0 0 0 0 0 25
2019/2020432 174 4 32 9 37 9 4 1 16 16 48 82
2020/2021430 6 32 54 35 59 76 39 13 47 13 36 20
2021/2022722 10 1 7 1 10 29 11 22 114 38 145 334
2022/2023769 162 57 14 64 95 88 4 71 122 48 38 6
2023/2024448 43 82 65 41 41 22 23 83 24 20 4 0
Totale 3.405